FDA Clearance Tracker · P110027-S012
therascreen KRAS RGQ PCR KIT
Last checked: Nov 20, 2026Latest source record: May 28, 2021 (this decision)Source: openFDAMethods & limitations
Decided
May 28, 2021
Approved
Time to decision
107 days
Received Feb 10, 2021. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Panel Track
Device class
Class III
The decision
- FDA number
- P110027-S012
- Device name
- therascreen KRAS RGQ PCR KIT
- Applicant
- QIAGEN GmbH
- Applicant location
- Hilden
- Received
- Feb 10, 2021
- Decided
- May 28, 2021
- Decision
- Approved
- Supplement type
- Panel Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P110027
Device type
- Device type
- Somatic gene mutation detection system (OWD)
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
Approval for expanding the indication to aid in the identification of non-small cell lung cancer patients whose tumors harbor KRAS G12C mutations and may benefit from treatment with LUMAKRA (sotorasib).
Source documents
Other decisions for QIAGEN GmbH
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
K262168 · Decided Sep 24, 2026 · 90 days after receipt
Device type: Gram-Negative Bacteria And Associated Resistance Markers (PEN) · Laboratory Medicine & Pathology
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.